Ausgabe 5/2019
Inhalt (10 Artikel)
Interplay between HSF1 and p53 signaling pathways in cancer initiation and progression: non-oncogene and oncogene addiction
Agnieszka Toma-Jonik, Natalia Vydra, Patryk Janus, Wiesława Widłak
Tumor-associated macrophages: role in cancer development and therapeutic implications
Arash Salmaninejad, Saeed Farajzadeh Valilou, Arash Soltani, Sepideh Ahmadi, Yousef Jafari Abarghan, Rhonda J. Rosengren, Amirhossein Sahebkar
Recent advances in the clinical development of immune checkpoint blockade therapy
Atefeh Ghahremanloo, Arash Soltani, Seyed Mohamad Sadegh Modaresi, Seyed Isaac Hashemy
Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy
Ginés Luengo-Gil, Elena García-Martínez, Asunción Chaves-Benito, Pablo Conesa-Zamora, Esther Navarro-Manzano, Enrique González-Billalabeitia, Elisa García-Garre, Alberto Martínez-Carrasco, Vicente Vicente, Francisco Ayala de la Peña
Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway
Mahendra Seervi, S. Sumi, Aneesh Chandrasekharan, Abhay K. Sharma, T. R. SanthoshKumar
The role of TNF-α in chordoma progression and inflammatory pathways
Sukru Gulluoglu, Emre Can Tuysuz, Mesut Sahin, Cumhur Kaan Yaltirik, Aysegul Kuskucu, Ferda Ozkan, Altay Burak Dalan, Fikrettin Sahin, Ugur Ture, Omer Faruk Bayrak
Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells
Lihua Chen, Xi Cheng, Wenzhi Tu, Zihao Qi, Haoran Li, Fei Liu, Yufei Yang, Zhe Zhang, Ziliang Wang
Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration
Yvette J. E. Sloot, Katrin Rabold, Thomas Ulas, Dennis M. De Graaf, Bas Heinhuis, Kristian Händler, Joachim L. Schultze, Mihai G. Netea, Johannes W. A. Smit, Leo A. B. Joosten, Romana T. Netea-Maier
Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells
Florian P. Reiter, Gerald Denk, Andreas Ziesch, Andrea Ofner, Ralf Wimmer, Simon Hohenester, Tobias S. Schiergens, Matilde Spampatti, Liangtao Ye, Timo Itzel, Stefan Munker, Andreas Teufel, Alexander L. Gerbes, Julia Mayerle, Enrico N. De Toni
Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial
Stéphanie Zunder, Priscilla van der Wilk, Hans Gelderblom, Tim Dekker, Christoph Mancao, Anna Kiialainen, Hein Putter, Rob Tollenaar, Wilma Mesker